Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track OLMA with free AI briefings, catalyst countdowns, and dilution alerts.

OLMA · Olema Oncology, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$413.8M Cash on Hand
26.7mo Cash Runway
23.8% Short Interest
$35.5 Analyst Target (10)
Follow OLMA by email Get an email when OLMA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about OLMA, unsubscribe in one click. Privacy

📣 What OLMA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Palazestrant (OP-1250) Breast Cancer Phase 3 · NCT06016738 Active not recruiting
Atirmociclib Metastatic Breast Cancer Phase 1 · NCT05508906 Active not recruiting
KAT6 Inhibitor OP-3136 Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) Phase 1 · NCT06784193 Recruiting

Also used in these trials (approved or third-party drugs, not OLMA's own candidates): Anastrozole, Exemestane, Fulvestrant, Letrozole, Ribociclib, Alpelisib, Everolimus, Palbociclib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

OLMA holds $413.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $46.5M/quarter from operations, an estimated runway of 26.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 54 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OLMA files for a raise →

👥 Who Owns OLMA

Insiders 12.7% Other 5%+ holders 13.6% Institutions (254 holders) 73.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 12,075,062 13.78% 2026-06-30
BVF PARTNERS L P/IL
Director · +499,018 options
Insider 8,939,731 10.20% 2026-10-14
Bain Capital Life Sciences Opportunities 5%+ holder (13G) 7,473,238 8.53% 2026-03-31
JANUS HENDERSON GROUP Ltd. Institution (13G, 5%+) 6,318,050 7.21% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 6,244,212 7.13% 2026-06-30
Siren, L.L.C. Institution (13F) 4,856,949 5.54% 2026-09-30
Raymond Debbane 5%+ holder (13G) 4,461,949 5.09% 2026-03-16
State Street Corporation Institution (13F) 3,847,478 4.39% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 3,513,193 4.01% 2026-09-30
Cyrus Harmon
Director · +29,500 options
Insider 819,798 0.94% 2026-07-23
David C. Myles
CH. DISCOV. & NON-CLIN DEV OFF · +406,250 options
Insider 555,592 0.63% 2026-01-12
Andrew Rappaport
Director · +29,500 options
Insider 385,965 0.44% 2025-11-21

Share count 87,606,263 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-01
filed 2026-09-02
O'Byrne Jason
Option award (A) 650,000 – –
2026-07-24
filed 2026-07-27
Harmon Cyrus
Sale (S) 12,500 $11.71 702,770
2026-07-23
filed 2026-07-27
Harmon Cyrus
Sale (S) 12,500 $11.58 715,270
2026-06-18
filed 2026-06-23
BUTITTA CYNTHIA M
Option award (A) 29,500 – –
2026-06-18
filed 2026-06-23
BIOTECHNOLOGY VALUE FUND L P
Option award (A) 29,500 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full OLMA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OLMA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.